Nurix Therapeutics, Inc. (NRIX)
26.14
+0.82
(+3.24%)
USD |
NASDAQ |
Sep 04, 16:00
26.13
-0.01
(-0.04%)
After-Hours: 20:00
Nurix Therapeutics Research and Development Expense (Quarterly) : 85.40M for May 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| May 31, 2026 | 85.40M |
| February 28, 2026 | 81.94M |
| November 30, 2025 | 80.90M |
| August 31, 2025 | 84.09M |
| May 31, 2025 | 75.85M |
| February 28, 2025 | 67.31M |
| November 30, 2024 | 64.68M |
| August 31, 2024 | 53.09M |
| May 31, 2024 | 46.59M |
| February 29, 2024 | 47.96M |
| November 30, 2023 | 47.78M |
| August 31, 2023 | 45.90M |
| May 31, 2023 | 43.87M |
| February 28, 2023 | 44.06M |
| November 30, 2022 | 44.49M |
| Date | Value |
|---|---|
| August 31, 2022 | 46.30M |
| May 31, 2022 | 46.21M |
| February 28, 2022 | 42.15M |
| November 30, 2021 | 35.77M |
| August 31, 2021 | 30.21M |
| May 31, 2021 | 25.39M |
| February 28, 2021 | 22.36M |
| November 30, 2020 | 19.80M |
| August 31, 2020 | 18.34M |
| May 31, 2020 | 13.65M |
| February 29, 2020 | 12.48M |
| November 30, 2019 | 12.28M |
| August 31, 2019 | 10.41M |
| May 31, 2019 | 10.16M |
| February 28, 2019 | 9.788M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Monte Rosa Therapeutics, Inc. | 46.05M |
| Gilead Sciences, Inc. | 1.69B |
| TG Therapeutics, Inc. | 95.34M |
| Cue Biopharma, Inc. | 48.98M |
| Keros Therapeutics, Inc. | 22.33M |